

Midwest Kidney Network Recommended Treatment Goals 2017

Midwest Kidney Network’s annual recommended treatment goals are based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, The Dialysis Facility Report (DFR), and the performance standards identified in the Quality Incentive Program (QIP) where applicable. Other goals are based on available evidence-based guidelines.

We provide these improvement goals as assistance to dialysis facilities for their use in quality improvement and with meeting the QIP performance standards. The goals apply to the facility’s permanent adult dialysis population. **Throughout this document, mean value refers to the average of the last monthly value for 12 months.**

Anemia Management

- Facilities should dose ESAs to maximize the percent of patients with hemoglobin concentration 9 – 11.5 gm/dL¹
- Standardized Transfusion Rate (STrR) will be *as expected* as or *better than expected*.

Dialysis Adequacy

- 93.2% of all dialysis patients (HD and PD) will achieve a Kt/V ≥ 1.2 or ≥ 1.7 .

National Healthcare Safety Network (NHSN)

- Standardized Infection Ratio will be *as expected* or *less than expected*.
- Facility will report 12 months of event data into NHSN.

Vascular Access

- If $\geq 65\%$ AVF in use: Facility should demonstrate consistent improvement towards meeting facility-specific AVF goal²
- If $< 65\%$ AVF in use: Facility AVF rate will achieve an annual increase that equals at least the specific goal set for that facility.
- If $\leq 10\%$ catheter in use for ≥ 90 days: Facility should maintain or reduce that percent of 90 day catheters
- If $> 10\%$ but $\leq 12\%$: Facility goal is to achieve 10% or less 90 day catheters
- If $> 12\%$ catheters in use for ≥ 90 days: Facility goal is to reduce percent of 90 days catheters by 2% over baseline (August 2016)

Nutritional Status

- $\geq 80\%$ of hemodialysis patients will have mean serum albumin \geq the lower limit of normal (LLN), **and** $\geq 40\%$ of patients will have mean serum albumin ≥ 4 gm/dL
- $\geq 70\%$ of peritoneal dialysis patients will have mean serum albumin \geq the lower limit of normal (LLN), **and** $\geq 40\%$ of patients will have mean serum albumin ≥ 4 gm/dL

¹ Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Inter., Suppl* 2012; 2: 279-355 (Guidelines 3.4.3 and 3.5.1)

² The facility AVF goal is based on the following formula: $(68\% \text{ [CMS program goal]}) - (\text{facility baseline percent [AVF rate in August 2016]}) \times 30\%$

**Midwest Kidney Network
Recommended Treatment Goals
2017**

Bone and Mineral Metabolism

- $\geq 65\%$ of dialysis patients (HD and PD) will have a mean serum phosphorus of ≤ 5.5 mg/dL
- $< 10\%$ of patients will have mean serum phosphorus of > 8 mg/dL
- $\leq 1.9\%$ of dialysis patients (HD and PD) will have a mean uncorrected serum calcium concentration of > 10.2 mg/dL.
- 100% of patients will have PTH monitored at least every 3 months

Immunization

- $\geq 90\%$ of patients will receive immunization for influenza
- $\geq 80\%$ of patients will receive immunization for pneumonia
- $\geq 90\%$ of patients without natural immunity will receive immunization for hepatitis B
- $\geq 90\%$ of dialysis personnel will be immunized for influenza

Advance Care Planning

$\geq 95\%$ of patients will have documentation that advance care planning discussions were conducted within 6 months of initiating dialysis

Kidney Transplant Referral

$\geq 85\%$ of patients will be assessed by the nephrologist for kidney transplant candidacy or referral within 6 months of initiating dialysis demonstrated by medical record documentation

Home Dialysis Referral

$\geq 85\%$ of patients will be assessed by the nephrologist for home dialysis candidacy or referral within 6 months of initiating dialysis as demonstrated by documentation in the medical record

In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems

- ICH-CAHPS survey is offered to patients semi-annually using a third party, CMS-approved vendor
- ICH-CAHPS survey results equal to or greater than the 50th percentile for 2016

These 2017 treatment goals have been approved by Midwest Kidney Network's Medical Review Committee on 11/4/2016 and by the Board of Directors on 12/2/2016.